GENOMIC HEALTH, INC.
Presentation Operator MessageOperator (Operator)Good day, and welcome to Genomic Health Inc.'s...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.
| 1st Jan change | Capi. | |
|---|---|---|
| +33.63% | 50.85B | |
| -0.09% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.95% | 19.13B | |
| +8.61% | 13.05B | |
| +28.31% | 12.16B | |
| +24.73% | 12.08B |
